Ads
related to: hepatitis c clinical guidelines treatmentassistantmagic.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; [2] it is a type of viral hepatitis. [6] During the initial infection period, people often have mild or no symptoms. [ 1 ]
In the European Union it was approved in July 2016, for the treatment of chronic hepatitis C virus infection in adults. [7] The safety and efficacy of sofosbuvir/velpatasvir for a 12-week treatment was evaluated in three Phase III clinical trials of 1,558 subjects without cirrhosis or with compensated cirrhosis (mild cirrhosis). [13]
Elbasvir/grazoprevir, sold under the brand name Zepatier, is a fixed-dose combination for the treatment of hepatitis C, containing elbasvir (an inhibitor of hepatitis C virus's NS5A protein) and grazoprevir (an NS3/4A inhibitor). It is used to treat chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in both treatment-naïve and ...
The hepatitis C virus (HCV) [3] is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer ( hepatocellular carcinoma , abbreviated HCC) and lymphomas in humans.
The combination includes 400 mg sofosbuvir and 60 mg daclatasvir and has been used in clinical trials since 2015. [ 7 ] [ 8 ] [ 9 ] Sovodak was approved by the Iranian Food and Drug Administration in October 2015 [ 10 ] and is currently marketed in Iran as the treatment of choice for all genotypes of hepatitis C as recommended by the national ...
Simeprevir, sold under the brand name Olysio among others, is a medication used in combination with other medications for the treatment of hepatitis C. [2] It is specifically used for hepatitis C genotype 1 and 4. [2] Medications it is used with include sofosbuvir or ribavirin and peginterferon-alfa. [2] Cure rates are in 80s to 90s percent.
The guidelines are specifically designed for countries where no national guidelines exist or where there is no regional liver association issuing protocols for recommended procedures and treatment. [3] Her clinical trials work on hepatitis C was published in the New England Journal of Medicine [4] and she is director of clinical hepatology on a ...
The DAA drugs against hepatitis C are taken orally, as tablets, for 8 to 12 weeks. [56] The treatment depends on the type or types of hepatitis C virus that are causing the infection. [57] Both during and at the end of treatment, blood tests are used to monitor the effectiveness of the treatment and subsequent cure. [56]
Ads
related to: hepatitis c clinical guidelines treatmentassistantmagic.com has been visited by 10K+ users in the past month